Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tesmilifene + epirubicin + cyclophosphamide
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tesmilifene + epirubicin + cyclophosphamide is an investigational **three-drug combination chemotherapy regimen** primarily evaluated for the treatment of metastatic breast cancer. Tesmilifene is a non-steroidal antiestrogen compound studied for its chemosensitizing properties. Epirubicin is an anthracycline chemotherapeutic agent that inhibits DNA and RNA synthesis through topoisomerase II inhibition. Cyclophosphamide is an alkylating agent that cross-links DNA strands, leading to apoptosis in rapidly dividing cancer cells. The combination is intended to enhance antitumor effects with distinct, but complementary, mechanisms: tesmilifene may increase the efficacy of cytotoxic chemotherapy through potential modulation of drug resistance, epirubicin blocks cellular replication via DNA damage, and cyclophosphamide induces cell death by DNA alkylation[2].
- Other names
- tesmilifeneepirubicincyclophosphamide
02
Targets
DNATOP2A (DNA topoisomerase II)H (Histamine receptors)ABCB1 (P-glycoprotein)ER (Estrogen receptor)
Beyond the preview
Go deeper on tesmilifene + epirubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tesmilifene + epirubicin + cyclophosphamide.